Grauer Andreas 4

What Happened

• Andreas Grauer, Chief Medical Officer of Sagimet Biosciences, was granted an award of 264,759 derivative shares (an option-based award) on April 20, 2026. The grant shows $0.00 per share (no cash paid at grant) and is reported as an award/acquisition (code A) on Form 4. The Form 4 was filed on May 14, 2026.

Key Details

• Transaction date: April 20, 2026; Filing date: May 14, 2026 (filed late relative to the 2-business-day Form 4 rule).
• Grant: 264,759 derivative shares at $0.00 (award/option).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote (vesting): 25% of the shares underlying the option vest on April 20, 2027; the remaining 75% vests in 36 equal monthly installments thereafter, subject to continued service.
• Transaction code: A = award/grant of a derivative instrument.

Context

• This was a compensation grant (derivative/option) not an open-market purchase or sale. No shares were sold or immediately acquired; the award vests over time and requires future vesting/exercise before underlying shares would be owned or tradable.
• Such grants are common for executives as part of pay and retention; filing was late, which is a reporting compliance issue but does not by itself indicate trading intent.